How Much Does Vyleesi (Bremelanotide) Cost in Tennessee in 2026?

Brand-Name Vyleesi Pricing Across Tennessee

The manufacturer list price for Vyleesi (bremelanotide 1.75 mg subcutaneous autoinjector) sits at approximately $1,200 per month as of early 2026. Retail pharmacies across Tennessee, from Memphis to Knoxville, charge close to that figure for patients paying cash without insurance. Price variation between individual pharmacies is minimal because the drug has a single manufacturer and no generic equivalent.

Vyleesi reached the market in June 2019 after the FDA approved it as the first on-demand injectable treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA approval label). The approval rested on two Phase 3 trials (RECONNECT I and II), which randomized 1,247 premenopausal women with HSDD to bremelanotide 1.75 mg or placebo. Patients using bremelanotide reported a statistically significant increase in desire, measured by the Female Sexual Function Index desire domain score, and a significant reduction in distress related to low sexual desire compared with placebo (Kingsberg et al., Obstet Gynecol 2019). That clinical evidence forms the basis for coverage decisions Tennessee insurers make today.

Because each autoinjector delivers a single 1.75 mg dose and the label recommends no more than eight doses per month, a full month's supply at maximum use is eight injectors. Patients who use fewer doses per month will pay proportionally less if purchasing individual units, though pharmacies typically dispense a full carton. The $1,200 figure reflects a standard monthly supply.

Compounded Bremelanotide in Tennessee: Legality and Cost

Licensed 503A compounding pharmacies in Tennessee can legally prepare bremelanotide formulations. This is the most direct route to cutting costs.

Under federal law (the Drug Quality and Security Act, Section 503A), a compounding pharmacy may prepare a patient-specific prescription for bremelanotide as long as the pharmacist holds a valid Tennessee Board of Pharmacy license and the prescription originates from a licensed prescriber with a legitimate patient relationship (FDA 503A guidance). Bremelanotide does not appear on the FDA's "Difficult to Compound" list, and it is not a commercially available product in compounded vial form, which satisfies the legal basis for compounding.

The average price for compounded bremelanotide from a Tennessee-licensed 503A pharmacy runs approximately $140 per month. That is roughly 88% less than the brand-name product. The compounded version is typically dispensed as a multi-dose vial with syringes rather than single-use autoinjectors. Patients self-administer subcutaneous injections in the same manner, though the injection device differs.

A few considerations apply. Compounded medications do not undergo FDA manufacturing review. The Tennessee Board of Pharmacy inspects 503A pharmacies operating in the state, but batch-to-batch consistency depends on the individual compounder's quality controls. Patients should confirm that the compounding pharmacy holds current Tennessee licensure and follows USP 797 sterile compounding standards. A prescriber familiar with both the brand product and compounded alternatives can help weigh cost savings against quality assurance differences.

Tennessee Medicaid and Vyleesi

Tennessee Medicaid (TennCare) does not cover Vyleesi for HSDD as of 2026. The drug is excluded from TennCare's preferred drug list.

TennCare's formulary decisions are managed by Magellan Health and reviewed by the state's Drug Utilization Review Board. Vyleesi falls into a therapeutic category that TennCare has historically classified as non-essential, partly because HSDD treatment is viewed as elective rather than medically necessary by the state's coverage criteria. No exception or prior authorization pathway currently exists for Vyleesi under TennCare managed care organizations (MCOs) such as BlueCare, Amerigroup, or UnitedHealthcare Community Plan.

For TennCare enrollees with HSDD, the practical options are limited. Flibanserin (Addyi), the oral daily medication for HSDD, also lacks TennCare formulary coverage in most MCOs. The American College of Obstetricians and Gynecologists (ACOG) recognizes both bremelanotide and flibanserin as FDA-approved options for HSDD but does not mandate insurance coverage (ACOG Practice Bulletin on Female Sexual Dysfunction). Patients on TennCare who want bremelanotide would need to pay out of pocket, and the compounded route at $140 per month represents the most affordable option in this scenario.

Commercial Insurance Coverage for Vyleesi in Tennessee

Coverage through commercial plans in Tennessee varies significantly by carrier and employer group, but prior authorization is almost universally required.

BlueCross BlueShield of Tennessee (BCBST), the state's largest commercial insurer, has listed Vyleesi as a specialty pharmacy benefit on select plans. Coverage typically requires documentation of an HSDD diagnosis meeting DSM-5 criteria, failure of or contraindication to non-pharmacologic interventions, and prescriber attestation that the patient is premenopausal. The prior authorization process can take 5 to 14 business days. If approved, patient copays under BCBST specialty tiers run between $75 and $250 per month depending on the plan design.

Cigna and UnitedHealthcare plans sold on the Tennessee exchange have also covered Vyleesi on a case-by-case basis. Aetna's national formulary excludes Vyleesi in most plan designs, though employer-sponsored Aetna plans with open formularies may allow it. Patients should call the number on the back of their insurance card and ask two specific questions: (1) Is bremelanotide (Vyleesi) on my plan's formulary? (2) What are the prior authorization requirements?

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends pharmacotherapy for HSDD after behavioral and psychological interventions have been considered, which aligns with most insurers' step-therapy requirements (Endocrine Society guideline).

The Palatin Technologies Savings Card

Palatin Technologies, the maker of Vyleesi, offers a manufacturer savings card that reduces out-of-pocket costs for commercially insured patients. The card is not available to patients on government insurance (Medicare, Medicaid, Tricare, VA).

Here is how the program works in Tennessee. Eligible patients register through the Vyleesi website or receive a card from their prescriber. Once activated, the card applies at the pharmacy point of sale. For commercially insured patients whose plan covers Vyleesi, the savings card can reduce the copay to as low as $0 per fill, up to a maximum annual benefit (typically $3,600 per year). For patients whose commercial plan does not cover Vyleesi, the card may still reduce the cash price, though the discount is smaller and the monthly cost can remain several hundred dollars.

The savings card resets annually. Patients must re-enroll each calendar year. Tennessee pharmacies enrolled in the program's network process the card automatically through the adjudication system, so no mail-order step is required.

Two limitations deserve mention. First, the savings card has an annual cap. Patients using the maximum eight doses per month at list price would exceed the card's annual benefit in roughly three months. Second, the card cannot be combined with other manufacturer coupons or state pharmaceutical assistance programs. Patients who are uninsured or on Medicaid cannot use it at all.

How Vyleesi Telehealth Prescribing Works in Tennessee

Tennessee permits telehealth prescribing of Vyleesi, which expands access for patients in rural areas of the state.

The Tennessee Board of Medical Examiners allows prescribers to establish a patient-provider relationship via synchronous audio-video telehealth. A prescriber licensed in Tennessee can evaluate a patient for HSDD, confirm that the patient meets criteria (premenopausal, acquired and generalized HSDD, absence of contraindications), and write the prescription electronically. No in-person visit is required for the initial evaluation as long as the telehealth encounter meets the board's standard of care.

The RECONNECT trials excluded women with uncontrolled hypertension because bremelanotide can transiently raise blood pressure by 2 to 3 mmHg on average (Kingsberg et al., 2019). For this reason, the FDA label recommends blood pressure monitoring. During a telehealth visit, the prescriber may ask the patient to provide a recent blood pressure reading taken at home or at a pharmacy kiosk. Patients with a history of uncontrolled hypertension or cardiovascular disease may need an in-person assessment before receiving the prescription.

Several national telehealth platforms now serve Tennessee residents for HSDD evaluation and Vyleesi prescribing. Prescriptions can be sent to a Tennessee retail pharmacy, a mail-order pharmacy, or a compounding pharmacy, depending on whether the patient opts for brand-name or compounded bremelanotide. Telehealth visits for HSDD evaluation typically cost between $75 and $200 out of pocket when not covered by insurance.

Comparing Cost-Reduction Strategies for Tennessee Patients

The table below summarizes the primary options for lowering Vyleesi costs in Tennessee.

| Strategy | Estimated Monthly Cost | Eligibility | |---|---|---| | Cash pay, brand-name Vyleesi | ~$1,200 | Anyone with a prescription | | Commercial insurance + savings card | $0 to $250 | Commercially insured, not government insurance | | Commercial insurance without savings card | $75 to $400+ | Commercially insured with formulary coverage | | Compounded bremelanotide (503A) | ~$140 | Anyone with a prescription from a licensed prescriber | | TennCare (Medicaid) | Not covered | N/A |

For uninsured patients, compounded bremelanotide at $140 per month is the most cost-effective option by a wide margin. For commercially insured patients with plan coverage, the Palatin savings card can eliminate copays entirely, making brand-name Vyleesi essentially free up to the annual cap. Patients should run the numbers: if a commercial plan covers Vyleesi with a $150 copay and the savings card zeroes it out, that path beats the $140 compounded price while providing an FDA-reviewed product.

One additional option exists for patients willing to explore manufacturer patient assistance programs (PAPs). Palatin's PAP provides Vyleesi at no cost to patients who meet income eligibility criteria (generally below 300% of the federal poverty level) and lack prescription drug coverage. Tennessee patients can apply directly through Palatin's website or through NeedyMeds, which maintains an updated listing of PAP requirements (NeedyMeds resource database).

Clinical Considerations That Affect Cost

How often a patient uses Vyleesi directly impacts monthly spending, and clinical data suggest most women do not use the maximum eight doses per month.

In the RECONNECT trials, the median number of doses used per month was approximately 4 to 5 over the 24-week treatment period (Kingsberg et al., 2019). That means many patients need only half a full monthly supply. Patients paying cash for brand-name Vyleesi should ask their pharmacy whether partial-carton dispensing is available, though most pharmacies dispense full cartons. For compounded bremelanotide, the multi-dose vial format naturally accommodates variable dosing because patients draw only the volume they need.

The most common side effect is nausea, reported by approximately 40% of patients in the RECONNECT trials. About 13% experienced flushing, and 6.3% reported injection-site reactions. Nausea tends to decrease with repeated use. Some patients find that using an antiemetic 30 minutes before the bremelanotide injection reduces nausea enough to continue treatment. The FDA label limits use to no more than one dose per 24 hours and no more than eight doses per month based on the safety data from these trials (FDA label).

Skin hyperpigmentation is another consideration flagged on the label. In clinical studies, focal hyperpigmentation (darkening of skin on the face, gingiva, or breasts) occurred in a subset of patients. The hyperpigmentation did not fully resolve in all cases after discontinuation. This side effect does not directly affect cost but may influence treatment duration and therefore cumulative spending.

What Tennessee Patients Should Do Next

Start by confirming your insurance status. Call your insurer and ask specifically about bremelanotide coverage, prior authorization requirements, and which specialty pharmacy tier applies. If your plan covers Vyleesi, register for the Palatin savings card before filling the prescription.

If you are uninsured or on TennCare, contact a Tennessee-licensed 503A compounding pharmacy and request a quote for compounded bremelanotide 1.75 mg/dose subcutaneous vials. Confirm the pharmacy holds current Tennessee Board of Pharmacy licensure and follows USP 797 standards.

A telehealth consultation can initiate the entire process without leaving home. The prescriber will assess HSDD criteria, review your medical history (including blood pressure), and send the prescription electronically to your pharmacy of choice. At current compounded pricing, a Tennessee patient using 4 to 5 doses per month can expect to spend roughly $70 to $90 monthly, which makes bremelanotide one of the more affordable on-demand prescription treatments for HSDD available in the state.